Last reviewed · How we verify
NCT04652570
Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy
Phase 1, PHASE2 trial testing VB119 in Membranous Nephropathy in 6 participants. Terminated before completion.
21 November 2023
Quick facts
| Lead sponsor | Tenet Medicines |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 6 |
| Start date | 5 May 2021 |
| Primary completion | 21 November 2023 |
| Estimated completion | 15 August 2024 |
| Sites | 4 locations across United States |
Drugs / interventions tested
- VB119 — full drug profile →
Conditions studied
- Membranous Nephropathy — all drugs for Membranous Nephropathy →
Sponsor
Tenet Medicines — full company profile →
Who can join
18 and older, any sex, with Membranous Nephropathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a Phase 1b/2a, open-label, sequential-cohort, dose escalation, and dose expansion study to evaluate the safety, tolerability, PK, and PD of VB119 in subjects with primary MN
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
An Updated Review of Membranous Nephropathy.
Efe O, So PNH, Anandh U, Lerma EV, et al · · 2024 · cited 9× · PMID 38681023 · DOI 10.25259/ijn_317_23
Verify or expand the search:
- PubMed search for NCT04652570
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of VB119
Trials testing the same drug.
- NCT05441826 — Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS) · Phase 2 · terminated
Other recruiting trials for Membranous Nephropathy
Currently open trials in the same condition.
- NCT07389499 — A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediate · EARLY_PHASE1 · recruiting
- NCT06341205 — Personalized Rituximab Treatment Based on Artificial Intelligence in Membranous Nephropathy (iRITUX) · Phase 3 · recruiting
- NCT05732402 — An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases · Phase 1, PHASE2 · active not recruiting
- NCT05688865 — Correlation and Clinical Utility of Urinary Biomarker in Membranous Glomerulonephritis · recruiting
- NCT04571658 — NEPTUNE Match Study · NA · recruiting
Other Tenet Medicines trials
Trials by the same sponsor.
- NCT05441826 — Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS) · Phase 2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04652570 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tenet Medicines
- Last refreshed: 12 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04652570.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing